###### Strengths and limitations of this study

-   This will be a systematic scoping review examining pain associated with psoriasis.

-   We will search multiple sources of information, including grey literature.

-   Articles published at any time will be eligible; date of publication will be transparently reported and will allow a temporal analysis of the development of this research topic.

-   Outcomes and outcome measures reported in the different studies can be incomparable; still, we will report them transparently to inform readers about the potential methodological differences and deficiencies of the studies involved.

-   We will strive to include studies published in any language, but there is an option that we will not be able to enable the translation of all studies; this will be reported transparently.

Introduction {#s1}
============

[Psoriasis](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/psoriasis) is a chronic [inflammatory disease](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/inflammatory-disease), also recognised as one of the most common immune-mediated diseases,[@R1] affecting 1%--3% of people worldwide.[@R2] Common sites of involvement are scalp, extensor surfaces of the limbs, elbows and knees, sacral and genital regions, although it can also affect all other body areas.[@R2] Aside from visible skin lesions, other related signs and symptoms can have a strong impact on psychophysiological and social health.[@R4] Studies have demonstrated that over 90% of patients with psoriasis report physical skin symptoms,[@R5] among which are frequently skin pain and skin discomfort,[@R8] with more than 40% of these patients expressing the presence of skin pain.[@R10] Its impact on the quality of life, including body pain scores, can be comparable to that of other major medical conditions such as heart disease and diabetes.[@R4]

Pain is defined as an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage.[@R11] One of the pain classifications found in literature categorises pain as nociceptive or neuropathic.[@R12] Nociceptive pain is a result of actual or threatened damage of non-neural tissue and due to nociceptors activation, with normal functioning somatosensory nervous system.[@R12] Neuropathic pain, in contrast with nociceptive pain, is caused by a disease or lesion of the somatosensory nervous system.[@R12]

Besides skin pain, patients with chronic skin disorders, such as psoriasis, may also experience pain in other parts of the body. Pain that occurs in patients with psoriasis outside of the skin mostly affects joints and musculoskeletal areas and it probably occurs due to the association of psoriasis with different systemic comorbidities, including psoriatic arthritis.[@R15] Although symptoms such as itching and scaling tend to be more common than pain in psoriasis, the recent study emphasised that skin pain was strongly associated with comorbid psychiatric and medical conditions.[@R16] Skin pain in patients with psoriasis tends to have a great negative effect on patient's everyday life, including basic life needs, interpersonal relations[@R16] and work productivity.[@R18]

Considering reports indicating high prevalence and burden of pain in psoriasis, it is important to devote more attention to its epidemiology, diagnosis and management.

In the scientific literature, there is no available high-quality evidence synthesis about the pain associated with psoriasis. Pithadia *et al* have published a review devoted solely to cutaneous pain associated with psoriasis; additionally, that was a narrative review and not a systematic review or systematic scoping review.[@R19]

The purpose of this systematic scoping review is to systematically summarise evidence from research literature about any type of pain in patients with psoriasis (skin pain, pain in psoriatic arthritis, and/or other types of acute and chronic pain).

Methods and analyses {#s2}
====================

Study design {#s2-1}
------------

This will be a systematic scoping review. We designed and will report this Scoping Reviews (ScR) in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).[@R20]

Protocol and registration {#s2-2}
-------------------------

We developed this protocol a priori, and by submitting it to an open-access peer-reviewed journal, we would like to ensure its public accessibility and transparency of our methods.

Patient and public involvement {#s2-3}
------------------------------

We did not involve patients or the public in our work.

Eligibility criteria {#s2-4}
--------------------

We will include any type of studies on humans that have analysed any data related to pain associated with psoriasis. We will not use any restrictions regarding period, language or type of publication. We will exclude studies about pruritus because pain and pruritus are not the same symptoms.

Information sources {#s2-5}
-------------------

We will search the following information sources: MEDLINE, Embase and PsycINFO via OVID, as well as Cochrane Central Register of Clinical Trials (CENTRAL), Cochrane Database of Systematic Reviews (CDSR) via Cochrane Library, CINAHL via EBSCO, OpenGrey and ProQuest Dissertations and Theses Global. All databases will be searched from the date of their inception. After we identify eligible studies based on the search of those databases, we will additionally analyse all references and citations of those studies, to potentially find additional relevant studies. The date of the most recent search will be noted. All search results will be exported to EndNote citation software (EndNote, Clarivate Analytics, Philadelphia, PA, USA); duplicates will be removed via software, and then manually if needed.

Search {#s2-6}
------

A full search strategy for the selected databases is shown in [online supplementary appendix 1](#SP1){ref-type="supplementary-material"}. Our search strategies were created using a combination of various keywords for psoriasis and pain, using both controlled vocabulary and free text searching.
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Selection of sources of evidence {#s2-7}
--------------------------------

Screening, that is, selection of studies, will be conducted in two stages. First, bibliographic records obtained via database searching will be screened by two authors independently (ASV and DN). All records retained as relevant or potentially relevant will be obtained in full text. Second, all retrieved full texts will be screened by two authors independently (ASV and DN). Records retrieved via searching of citations and references of eligible studies will also be screened by the same two authors independently. Discrepancies in opinion regarding study eligibility will be resolved by discussion, and---if necessary, in consultation with the third author (LP). We will report which studies were excluded on the level of full-text assessments, with reasons.

Data charting process {#s2-8}
---------------------

Two authors (ASV and DN) will develop the data extraction form. This form will determine which variables to extract, and how. The form will be calibrated on 20 randomly selected studies. During the calibration exercise, the authors will independently extract the data, and then discuss results; we will update the form in an iterative process, if necessary. The final version of the data extraction form will be enclosed with the full report at the time of completion of this review.

Data items {#s2-9}
----------

We will extract the following items from eligible studies: name of the first author, country of authors' affiliations, year of publication, journal, aim, country where the study was conducted, study design, size of the study sample, type of study sample (ie, any type of psoriasis, or specific types of psoriasis), setting, outcomes and outcome measures analysed, numerical results reported, type of pain (cutaneous, psoriatic arthritis pain and pain in general) data on pain prevalence, pain intensity, quality, location and duration, and conclusions regarding pain in the context of psoriasis. We will also extract data on conflict of interest of authors of the eligible studies, as well as the type of funding.

Two researchers (ASV and DN) will extract data independently. Any discrepancies in data extraction will be resolved by discussion or consultation with the third author (LP) if necessary.

Critical appraisal of individual sources of evidence {#s2-10}
----------------------------------------------------

If we find any systematic reviews on this topic, we will assess them with the second version of A MeaSurement Tool to Assess systematic Reviews (AMSTAR-2), a tool for appraising systematic reviews.[@R21] If we find any randomised controlled trials or non-randomised studies of interventions, the risk of bias will be appraised using Cochrane risk of bias (RoB) tool[@R22] or risk of bias tool to assess non-randomized studies of interventions (ROBINS),[@R23] respectively. To appraise quantitative and qualitative studies, we will use a Mixed Methods Appraisal Tool, version 2018.[@R24]

Synthesis/presentation of results {#s2-11}
---------------------------------

We do not expect to find data relevant for conducting a meta-analysis; meta-analysis is not anticipated a priori in scoping reviews.[@R20] All information we find about the pain associated with psoriasis will be categorised and narrative evidence synthesis will be conducted. If possible, we will try to quantitatively summarise the extracted information.

Selection of sources of evidence {#s2-12}
--------------------------------

In our results, we will report numbers of sources of evidence, screened, assessed for eligibility, and included in the systematic scoping review, with reasons for exclusions at each stage, via a flow diagram, that is, PRISMA flow chart.[@R20] We will provide elaborate information for included studies in a table titled 'Characteristics of included studies', as well as a list of excluded studies---with reasons and references.

Characteristics of sources of evidence {#s2-13}
--------------------------------------

For each included study, we will present the following characteristics: studies' place of origin, aims, design, methods and potentially other relevant information.

Ethics and dissemination {#s2-14}
------------------------

The proposed study will not recruit or collect data directly from human participants. We will only use published data and therefore ethics approval is not required. Our findings will be disseminated via peer-reviewed manuscript and conference reports.

Discussion {#s3}
==========

With this systematic review, we expect to create a comprehensive evidence synthesis about pain reported as associated with psoriasis. We are aware that we will surely find heterogeneous types of studies and pain-related topics within the context of psoriasis, but such heterogeneity is inherent in scoping reviews; this is highlighted in the introductory parts of the PRISMA-ScR ('summarise findings from a body of knowledge that is heterogeneous in methods or discipline').[@R20] Our eligibility criteria will allow for the inclusion of older articles. However, this will be transparently reported and will allow us to clearly depict the evolution of this research topic. Conducting the proposed scoping review will enable us to provide evidence mapping and conduct of future focused systematic reviews.

The strength of this study is that this will be the first systematic scoping review on the proposed topic. Additionally, we chose to search multiple information sources, which should enable effective literature searching. There are no uniform guidelines for sources that should be searched in scoping reviews because this ultimately depends on the topic. For example, PRISMA extension for scoping reviews simply asks authors to transparently report which information sources were searched and encourages authors to report search strategy for at least one database.[@R20] Instructions in this and other guidance provide only the following suggestion 'The search strategy should be comprehensive in order to identify both published and unpublished (grey literature) literature'. Joanna Briggs Institute manual for scoping reviews recommends searching 'at least two appropriate online databases relevant to the topic'.[@R25] Due to the lack of uniform guidance, we have suggested using a very comprehensive search strategy, which involves six databases and two sources of grey (unpublished) literature.

Expected timeline {#s3-1}
-----------------

The authors will not start working on the conduct of this scoping systematic review until the publication of this protocol.
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